-
Bio-heart’s Iberis RDN System Completes First Commercial Surgery in Germany
•
China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced the successful completion of its first commercial surgery using the Iberis multi-electrode renal radiofrequency denervation (RDN) system in Germany. The procedure was performed by Dr. Saarraaken Kulenthiran at the University Hospital of Saarland, with no complications or adverse events reported.…
-
Bio-heart’s Iberis System Approved by NMPA for Hypertension Treatment
•
China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced that its subsidiary, Shanghai Angiocare Medical Technology Co., Ltd, has received market approval from the National Medical Products Administration (NMPA) for its multipole renal arterial radiofrequency ablation system, Iberis. The device is approved as an adjuvant therapy for refractory hypertension…
-
Shanghai Pharmaceuticals Halts Development of I001-B, I022, and C012 in the US
•
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) has declared the termination of clinical trials and subsequent development of I001-B (US), I022 (US), and C012 (US). This decision comes after a comprehensive evaluation of the future market value, business collaboration, and development investment required for these projects. I001-B and I022…
-
Innovent Biologics and Sanegene Bio Commence Phase I Clinical Trial for Hypertension siRNA Drug
•
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, in collaboration with Sanegene Bio USA Inc., has announced the dosing of the first patient in a Phase I First-in-Human (FIH) clinical trial for their siRNA drug candidate, IBI3016. This investigational therapy targets angiotensinogen (AGT) and is being…
-
Suzhou Sanegene Bio Receives NMPA Approval for Clinical Trial of Antihypertensive siRNA Drug
•
Suzhou Sanegene Bio Inc., a leading RNAi specialist with research and development centers in both the US and China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug SGB-3908. This antihypertensive siRNA drug has been co-developed with Innovent Biologics,…
-
Novartis Reports 11% YOY Sales Growth in Q1 2024, Led by Entresto and Cosentyx
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported an 11% year-on-year (YOY) increase in constant currency terms during the first quarter of 2024, reaching USD 11.8 billion in sales. The growth was driven by strong performances across all key brands and geographies. The top-selling and growth-driving drugs included hypertension therapy…
-
Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor
•
Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its generic version of Concor, which contains bisoprolol and amlodipine, a compound preparation used as an alternative therapy for hypertension. The approval signifies that Easton’s…
-
Golden Leaf Med Tec Secures Series D Funding to Advance Hypertension and Diabetes Treatments
•
Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China, has reportedly secured “hundreds of millions” of renminbi in a Series D financing round. The round was led by ZhongPing Capital, with participation from Shanghai Healthcare Capital, Dingxin Capital, and Morning Spring Venture. The funds…
-
Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus
•
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales for the last financial year, amassing USD 45.4 billion—a 10% year-on-year (YOY) increase in constant currency terms, as per the 2023 financials released this week. This achievement marks Novartis’s inaugural annual report following the strategic…
-
Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth
•
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a net sales decrease of -4.1% year-on-year (YOY) but an increase of 3.2% in constant currency terms, reaching EUR 11.96 billion (USD 12.64 billion). Despite maintaining the forecast for 2023 earnings per share (EPS) growth, Sanofi…
-
Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff
•
Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since the company sharpened its focus on innovative medicines following the spinoff of Sandoz (SWX: SDZ) earlier this month. The financials reveal a robust performance with net sales reaching USD 34.0 billion for the first nine…
-
Novo Nordisk Strikes $1.3 Billion Deal for KBP Biosciences’ Ocedurenone
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) announced a significant deal this week, valued at up to USD 1.3 billion, for the acquisition of the potential best-in-class antihypertensive drug ocedurenone from Singapore’s KBP Biosciences. The transaction, anticipated to close by the end of the year, is subject to meeting customary…
-
MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has presented interim data from Phase III and extension studies for its potential first-in-class biologic sotatercept, which is being investigated for the treatment of pulmonary arterial hypertension (PAH). The late-stage trial indicated that the activin signaling inhibitor led to a reduction in right…
-
Roche and Alnylam’s Zilebesiran Achieves Primary Endpoint in Hypertension Phase II Trial
•
Roche (SWX: ROG) and Alnylam (NASDAQ: ALNY) have announced that a Phase II trial for their RNAi therapeutic, zilebesiran, has successfully met its primary endpoint of significantly reducing 24-hour mean systolic blood pressure (SBP) at month three in patients with mild-to-moderate hypertension. The results also demonstrated reductions in SBP and…
-
Chia Tai Tianqing’s Generic Entresto Approved by NMPA, Launch Expected in 2026
•
The National Medical Products Administration (NMPA) website has indicated that Chia Tai Tianqing’s generic version of Swiss pharmaceutical giant Novartis’s heart failure therapy Entresto (sacubitril, valsartan) has been approved for marketing. However, the generic version will not be launched until 2026 when the originator’s patent expires. This follows the approval…
-
Nanjing F&S Pharmatech Secures First Generic Approval for Novartis’s Entresto in China
•
Nanjing F&S Pharmatech Co., Ltd, a China-based pharmaceutical company, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its generic version of Novartis’s (NYSE: NVS) heart failure therapy, Entresto (sacubitril, valsartan). This marks a significant milestone as Nanjing F&S’s version, an in-house developed…
-
Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment
•
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam (NASDAQ: ALNY), securing rights to co-develop and co-commercialize Alnylam’s zilebesiran, a Phase II stage RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension. Financial Terms and Collaboration DetailsUnder the agreement, Roche will pay Alnylam…
-
Novartis Q2 2023 Results Exceed Expectations with 9% YOY Sales Growth
•
Swiss pharmaceutical major Novartis AG (NYSE: NVS) has reported its financial results for the second quarter of 2023, with both sales and profits surpassing analyst forecasts. Net sales for the quarter reached USD 13.622 billion, marking a 9% year-on-year (YOY) increase in constant currency terms. Core net income also saw…
-
Bio-heart’s Iberis-HTN Study Shows Promising Results in Treating Primary Hypertension
•
China-based Bio-heart Biological Technology Co., Ltd. (HKG: 2185) and its holding subsidiary Angiocare have announced the clinical results for the Iberis-HTN trial at the China Interventional Therapeutics 2023 conference. Iberis-HTN is a prospective, multicenter, blinded, randomized controlled trial designed to evaluate the safety and efficacy of the Iberis Multi-Electrode Renal…
-
Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1
•
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with fellow Chinese firm Zhejiang Anglikang Pharmaceutical Co. Ltd (SHE: 002940) concerning Sun-Novo’s drug candidate, NHKC-1. This development marks a collaborative effort between the two companies to co-develop a treatment for primary hypertension. NHKC-1: A Drug…
